TRILC Financials - Turk Ilac ve Serum Sanayi AS | Makkler
TR
Turk Ilac ve Serum Sanayi AS TRILC
BIST · Türkiye · Health Technology
₺0.7100-0.02 (-2.74%)
Market open· · TRY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Revenue and net income (annual)
RevenueNet Income
2021
₺672.60M
₺37.14M
2022
₺1.64B
₺-81.65M
2023
₺2.77B
₺152.63M
2024
₺3.36B
₺94.71M
2025
₺4.99B
₺-685.16M
Valuation (computed from filings)
Trailing 12 months · 2026-03-31
Earnings per share
₺-0.08
Book value / share
₺1.92
P/B
0.4x
Revenue / share
₺5.34
P/S
0.1x
Free cash flow yield
24.1%
Return on equity
-4.2%
Operating margin
27.3%
Net margin
-1.5%
Liabilities / equity
3.3x
Diluted shares
1.04B
These ratios divide the lines in the statements below by the current price; both inputs of every value are visible on this page. The P/E on the overview comes from the same calculation. P/E and P/S are left blank for loss-making companies or where revenue is not reported. Not investment advice.
Taken from the financial statements the company files with Turkey's Public Disclosure Platform (KAP), in Turkish lira. Non-financial companies restate prior periods for inflation (IAS 29) into the purchasing power of their latest report, so every column is in the same, current lira - older years therefore read higher than the figures originally published. The "LTM" column is the last fiscal year plus the current year to date, minus the same period a year earlier. Not investment advice.